advanced cardiovascular disease News
-
Elucid Presents Results of the EVAPORATE Study at ESC Preventive Cardiology 2021 Late Breakers
BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced that first author and Elucid founder Andrew Buckler presented findings today from the EVAPORATE (Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking ...
By Elucid
-
Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis
BOSTON – June 22, 2022 – Elucid, a company developing a novel, non-invasive medical software to comprehensively characterize cardiovascular disease, announced the closing of a $27 Million Series B financing round. The round was led by an undisclosed strategic investor, with participation from Biovision Ventures, a new Europe-based fund, and existing investors, including MedTex ...
By Elucid
-
Elucid announces American Medical Association (AMA) instates CPT Code for Lipid-Rich Necrotic Core Quantification to Assess Atherosclerotic Plaque Stability
BOSTON – December 17, 2021 – Elucid, a Boston-based medical technology company harnessing scientific imaging and artificial intelligence to enable the precise diagnosis and treatment of the world’s leading cause of death announced a new CPT code unique to its Plaque IQ technology for CT angiography. Plaque composition, specifically lipid-rich necrotic core, has been identified ...
By Elucid
-
Elucid Secures $8 Million in Series A Funding Led by MedTex Ventures and Global Health Impact Fund
BOSTON – Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, today announced $8 Million in Series A financing led by MedTex Ventures and Global Health Impact Fund. New and existing investors Checkmate Capital, IAG Capital, BlueStone Venture Partners, University of Michigan – Wolverine Venture Fund, Willamette Valley Capital LLC, ...
By Elucid
-
Elucid Eyes Big Opportunity to Save Lives with Software Amidst Major Guideline Changes
BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, expects newly issued guidelines will be a catalyst for non-invasive image, revolutionizing the way patients with coronary artery disease are diagnosed and treated. In a highly anticipated document published online yesterday in Circulation and the Journal of ...
By Elucid
-
Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer
BOSTON – July 26, 2022 – Elucid, a novel non-invasive software company providing physicians with AI-powered imaging to characterize cardiovascular disease, is pleased to announce that Todd C. Villines, MD, is joining the company as Chief Medical Officer. Dr. Villines will be leading clinical strategy development and execution for Elucid’s commercial and in-development ...
By Elucid
-
Elucid Presents Data Demonstrating Its AI Software Can Uniquely Quantify Key Drivers of Heart Attack and Stroke from Computed Tomography
BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced today that its founder Andrew Buckler will present findings from two separate studies at the virtual Society of Cardiovascular Computed Tomography (SCCT) 16th Annual Scientific Meeting. The studies ...
By Elucid
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you